Remarkable success has been encountered with CD19 specific CAR-T cells, leading the approval by the FDA in late 2017 of two approaches, Kymriah (tisagenlecleucel, CTL019, Novartis, Basel, Switzerland) and Yescarta (axicabtagene ciloleucel, Axi-cel, Gilead/Kite Pharma, Santa Monica, CA, USA) for the treatment of relapsed/refractory B cell acute lymphocytic leukemia (r/r B-ALL) and relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL), respectively [4]. Here, CD19 is linked to acute lymphoblastic leukemia.